Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer.

Guilhem RoubaudGerhardt AttardMartin BoegemannDavid OlmosMarco TrevisanLaurent AntoniKatie PascoeCamille CaponeSuzy Van SandenMahmoud HashimStephen PalmerKim Chi

Published in: European journal of cancer (Oxford, England : 1990) (2024)

NCT03748641 (MAGNITUDE).

Keyphrases

prostate cancer
radical prostatectomy
open label
randomized controlled trial
clinical trial
placebo controlled
study protocol